Immunomedics, Inc. (IMMU) Highlights Clinical Pipeline For Solid Cancer And Lupus Therapy At R & D Day
4/24/2014 9:31:16 AM
MORRIS PLAINS, N.J., April 23, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced a historical milestone in the Company's listing at the NASDAQ stock market, which is going on 30 years strong. Only a small, elite group of biopharmaceutical companies has this longevity.
Help employers find you! Check out all the jobs and post your resume.
comments powered by